Why Did CVS Group plc Shares Rise on 13 November 2026?

CVS Group plc (LSE:CVSG) shares rose 1.14% to 1,425p on 13 November 2026. The veterinary services provider remains in focus after its final results for the year ended 30 June 2026, published on 24 September 2026.

The results showed higher Revenue and adjusted earnings, a larger dividend, continued share Buybacks and further expansion in Australia.

Key Highlights

Group revenue rose 5.9% to £712.8m, with like-for-like sales growth of 2.1%. Adjusted EBITDA was £141.5m, equal to a Margin of 19.9%, and adjusted Earnings per share rose 6.9% to 85.6p.

Statutory profit before tax was £32.0m. The board recommended a final Dividend of 9.0p per share, up 5.9% from 8.5p.

Australian revenue increased 52% to £79.1m, with practice sites rising to 57 from 43.

About CVS Group plc

CVS Group is a UK-listed veterinary group and a leading provider of veterinary services. It operates general practices, referral and specialist hospitals, and complementary services that support animal health.

Its integrated model brings together clinical care, diagnostics and related services, while its Australian division is now a meaningful part of group income, contributing more than a tenth of revenue.

FY26 Financial Performance

Revenue of £712.8m compares with £673.2m a year earlier. The group invested £36.4m in property, plant and equipment and other capital projects, equal to about 5.0% of revenue.

Net bank borrowings rose to £199.6m, reflecting Australian acquisitions and the start of the buyback programme, with Leverage of around 1.63x. The group also refinanced its £350m Loan facilities during the year.

Australian Expansion

During the year, CVS completed six Australian acquisitions covering 14 practice sites, in addition to a minority interest buyout. Australian revenue reached £79.1m compared with £52.1m, and management has indicated further Acquisition opportunities in both Australia and the UK.

This expansion widens the group's geographic base and offers a second platform for growth alongside its UK operations.

Capital Allocation and Buybacks

The company completed a £20m share buyback and announced a further £50m programme in May 2026, of which £11.7m had been completed by 30 June 2026. Together with the higher dividend, these steps show how cash generation is being allocated between Investment and Shareholder returns.

Understanding Like-for-Like Growth and EBITDA

Like-for-like sales growth compares revenue from practices that were open in both periods, which strips out the effect of acquisitions. CVS recorded 2.1% on this measure, so most of the 5.9% revenue growth came from inorganic expansion and acquired sites rather than from existing practices alone.

Adjusted EBITDA of £141.5m reflects earnings before interest, tax, Depreciation and amortisation, adjusted for certain items. At a margin of 19.9%, it provides a view of operating profitability that is separate from financing and accounting choices.

Why Veterinary Services Attract Long-Term Interest

Pet ownership creates recurring Demand for routine care such as vaccinations, check-ups, diagnostics and medication, alongside less frequent referral work. Integrated groups can spread purchasing, technology and Training costs across a large network of practices.

CVS has also pursued an investment approach that sets aside around £30m a year for capital projects, which supports practice upgrades and clinical capacity. Combined with disciplined acquisition spending, this underpins its plan to extend its network in both the UK and Australia.

Australia matters here because the market is fragmented, with many independent practices, which creates a steady flow of potential acquisition targets. Each integrated site can also draw on group purchasing, technology and clinical training.

Key Growth Catalysts

Catalysts include further bolt-on acquisitions in Australia and the UK, improving like-for-like sales, and benefits from integrating newly acquired practices. Management has said it expects around £50m a year to be directed to acquisitions and about £30m a year to total capital investment.

Factors to Monitor

Management noted that trading in the final quarter was affected by softer UK consumer confidence and unusually hot weather, which led some customers to defer routine appointments. Investors may follow how like-for-like sales respond as conditions change, along with leverage and integration of new practices.

What Investors Should Watch Next

Key items include trading updates for the new financial year, progress of the buyback, Australian acquisition activity, leverage levels and the dividend payment timetable.

Conclusion

CVS Group plc (LSE:CVSG) rose 1.14% to 1,425p on 13 November 2026. FY26 revenue growth of 5.9%, a higher dividend and a 52% increase in Australian revenue give the market clear reference points as the group continues to scale.